Farmacoriflessioni
Vaccini anti-rotavirus. quale? quando? perché? per chi?
ROTAVIRUS VACCINES
MASSIMO FONTANA
Struttura Complessa di Pediatria, Ospedale dei Bambini “V. Buzzi”, Milano
Marzo 2007 - pagg. 173 -175
Abstract
Two new Rotavirus vaccines are being dispensed soon in Italy. They differ strongly in composition
and suggested schedule. Available studies do not allow direct comparisons (severity
scales for gastroenteritis are different, as are the cut-off points). Safety for the first dose to be
administered beyond the age of three months has not yet proved, so “catch-up” vaccination
should be discouraged. Other relevant points which still need definite answers are the possible
interaction with oral poliovirus vaccine (especially relevant in developing countries)
and the recently suggested role of Rotavirus in the pathogenesis of celiac disease. Moreover,
when performing cost-efficacy analysis about Rotavirus vaccination, one should bore in mind
the still high number of inappropriate hospital admission for acute gastroenteritis in Italy.
Parole chiave
Classificazione MeSH
Bibliografia
1. Ruiz-Palacios GM, Pérez-Schael I, Velazquez
FR, et al. Safety and efficacy of an attenuated
vaccine against severe Rotavirus gastroenteritis.
N Engl J Med 2006;354:11-22.
2. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine reassortant Rotavirus vaccine. N Engl J Med 2006;354:23-33.
3. Digest. Vaccini anti-Rotavirus. Medico e Bambino 2006;25(1):49-50.
4. Salins B, Pérez-Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated Rotavirus vaccine, RIX4414. Pediatr Infect Dis J 2005;24:807-16.
5. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004;144:184-90.
6. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22:259-67.
7. Murphy T, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral Rotavirus vaccine. N Engl J Med 2001; 344:564-72.
8. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZl. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005;192:S36-43.
9. Soriano-Gabarrò M, Mrikowicz J, Vesikari T, Verstraeten T. Burden of Rotavirus Disease in European Union Countries. Pediatr Infect Dis J 2006;25:S7-11.
10. Kilgore PE, Holman RC, Clarke MJ, Glass RI. Trends of diarrhoeal disease-associated mortality in US children, 1968 through 1991. JAMA 1995;274:1143-8.
11. Zanoni G, Navone R, Lunardi C, et al. In celiac disease a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. Plos Med 2006;3:1637-53.
2. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine reassortant Rotavirus vaccine. N Engl J Med 2006;354:23-33.
3. Digest. Vaccini anti-Rotavirus. Medico e Bambino 2006;25(1):49-50.
4. Salins B, Pérez-Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated Rotavirus vaccine, RIX4414. Pediatr Infect Dis J 2005;24:807-16.
5. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004;144:184-90.
6. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22:259-67.
7. Murphy T, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral Rotavirus vaccine. N Engl J Med 2001; 344:564-72.
8. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZl. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005;192:S36-43.
9. Soriano-Gabarrò M, Mrikowicz J, Vesikari T, Verstraeten T. Burden of Rotavirus Disease in European Union Countries. Pediatr Infect Dis J 2006;25:S7-11.
10. Kilgore PE, Holman RC, Clarke MJ, Glass RI. Trends of diarrhoeal disease-associated mortality in US children, 1968 through 1991. JAMA 1995;274:1143-8.
11. Zanoni G, Navone R, Lunardi C, et al. In celiac disease a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. Plos Med 2006;3:1637-53.
Corrispondenza: massimo.fontana@unimi.it